These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19236278)

  • 1. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.
    Herrero R
    J Infect Dis; 2009 Apr; 199(7):919-22. PubMed ID: 19236278
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the burden of cervical cancer and HPV-related diseases through vaccination. Introduction.
    Cox JT
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s3-4. PubMed ID: 16520682
    [No Abstract]   [Full Text] [Related]  

  • 4. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time.
    Bosch FX
    J Natl Cancer Inst; 2009 Jun; 101(11):771-3. PubMed ID: 19470950
    [No Abstract]   [Full Text] [Related]  

  • 6. Harnessing the power of prevention: human papillomavirus vaccines.
    Mayeaux EJ
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic HPV vaccination for the prevention of cervical cancer.
    Hernandez BY
    Hawaii Med J; 2007 Jul; 66(7):190-1. PubMed ID: 17879858
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards global prevention of human papillomavirus-induced cancer.
    Roden RB; Gravitt P; Wu TC
    Eur J Immunol; 2008 Feb; 38(2):323-6. PubMed ID: 18228245
    [No Abstract]   [Full Text] [Related]  

  • 10. Human papillomavirus vaccine: widening the scope for cancer prevention.
    No JH; Kim MK; Jeon YT; Kim YB; Song YS
    Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
    Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
    Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new era of cervical cancer prevention: HPV vaccination.
    Monk BJ; Herzog TJ
    Gynecol Oncol; 2008 May; 109(2 Suppl):S1-3. PubMed ID: 18482553
    [No Abstract]   [Full Text] [Related]  

  • 13. One in four California adolescent girls have had human papillomavirus vaccination.
    Grant D; Kravitz-Wirtz N; Breen N; Tiro JA; Tsui J
    Policy Brief UCLA Cent Health Policy Res; 2009 Feb; (PB2009-3):1-6. PubMed ID: 19288623
    [No Abstract]   [Full Text] [Related]  

  • 14. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The human papilloma virus, the vaccines, and oral and oropharyngeal squamous cell carcinoma: what every dentist should know.
    Closmann JJ
    Gen Dent; 2007; 55(3):252-4; quiz 255, 264. PubMed ID: 17511372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and secondary prevention of cervical cancer--opportunities and challenges.
    Markowitz LE; Unger ER; Saraiya M
    J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638
    [No Abstract]   [Full Text] [Related]  

  • 17. Cervical cancer: the second-generation vaccines move forward.
    Tuma RS
    J Natl Cancer Inst; 2009 Jun; 101(11):774-5. PubMed ID: 19470948
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of prophylactic HPV vaccines.
    Gissmann L; Müller M
    Coll Antropol; 2007 Apr; 31 Suppl 2():113-5. PubMed ID: 17598512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
    Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of cervical cancer by HPV vaccine].
    Konno R
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):236-9. PubMed ID: 20235395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.